+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Whole-genome amplification for the detection of molecular targets and minimal residual disease monitoring in acute lymphoblastic leukaemia



Whole-genome amplification for the detection of molecular targets and minimal residual disease monitoring in acute lymphoblastic leukaemia



British Journal of Haematology 165(3): 341-348



Accurate genomic characterization requires sufficient amounts of optimal quality DNA. An approach for increasing the DNA amount is the whole-genome amplification (WGA) method. We applied WGA to the molecular quantification and minimal residual disease (MRD) evaluation of acute lymphoblastic leukaemia (ALL), aiming to compare the results obtained from genomic DNA and amplified DNA with WGA, and to evaluate the applicability and the reliability of WGA-DNA. Twenty paired samples from adult ALL patients were sequenced to identify the functional germline V-D-J segment at diagnosis; real-time quantitative polymerase chain reaction (RQ-PCR) quantitative analysis was performed both at diagnosis and follow-up. Genomic DNA and WGA-DNA screening identified equivalent 87 rearrangements. At diagnosis, the quantitative evaluation of genomic DNA samples showed 1 logarithm difference to WGA-DNA samples; these levels are comparable, being within the degree of acceptability and confidence. In the follow-up samples, RQ-PCR analysis on genomic DNA and WGA showed concordant MRD results in 16/18 samples, while 2/18 were MRD-positive outside the quantitative range by RQ-PCR (i.e. <5 × 10(-5)) on genomic DNA and MRD-negative on WGA-DNA. WGA-DNA enables: (i) the design of accurate targets for MRD evaluation in ALL patients, (ii) accurate disease quantification at diagnosis, (iii) MRD quantification comparable to genomic DNA.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056942338

Download citation: RISBibTeXText

PMID: 24446831

DOI: 10.1111/bjh.12744


Related references

Detection and quantitative monitoring of minimal residual disease in acute lymphoblastic leukaemia patients. British Journal of Cancer 86(Suppl. 1): S40, 2002

Technical scheme of minimal residual disease detection with Ig/TCR rearrangements as molecular targets in childhood acute lymphoblastic leukemia. Zhonghua Er Ke Za Zhi 49(3): 165-169, 2011

Molecular monitoring of minimal residual disease in childhood acute lymphoblastic leukaemia using antigen receptor gene rearrangements is highly feasible for disease stratification and prognostication. Annals of the Academy of Medicine Singapore 32(5 Suppl): S31-S33, 2003

Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13(1): 110-118, 1999

The detection of minimal residual disease in acute lymphoblastic leukaemia. Blood Reviews 6(2): 68-82, 1992

Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. British Journal Of Haematology. 99(2): 314-319,., 1997

Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. British Journal of Haematology 144(1): 107-115, 2009

Molecular detection of TEL-AML1 transcripts as a diagnostic tool and for monitoring of minimal residual disease in B-lineage childhood acute lymphoblastic leukemia. Molecules and Cells 10(1): 90-95, 2000

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 351(9102): 550-554, 1998

The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. British Journal of Haematology 83(3): 412-418, 1993

Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia. Best Practice and Research. Clinical Haematology 15(1): 71-90, 2002

Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. British Journal of Haematology 116(3): 686-694, 2002

Immunoglobulin gene rearrangement in detection of minimal residual disease in acute lymphoblastic leukaemia. Journal of Ayub Medical College Abbottabad 25(1-2): 159-161, 2014

Genetic changes: relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia. Bailliere's Clinical Haematology 7(2): 183-233, 1994